Brigatinib was capable of suppressing the proliferative potential of both ALK-positive H3122 and H2228 NSCLC cells, as well as ALK-negative A549 (NSCLC), Hep3B (HCC), Du145 (Prostate), and HCT116 (Colon) cell lines, suggesting that brigatinib possesses an ALK-independent antitumor potential. Here, ALK is linked to hepatocellular carcinoma.